Literature DB >> 15301634

A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

Jenny L Wiley1, Kari L LaVecchia, Natalie E Karp, Sanjitha Kulasegram, Anu Mahadevan, Raj K Razdan, Billy R Martin.   

Abstract

Efforts to determine whether Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and anandamide elicit similar discriminative stimulus effects have yielded conflicting results. The difficulty in establishing a discriminative cue to anandamide may be due to its metabolic instability. Rats were trained to discriminate either Delta(9)-THC or O-1812, a metabolically stable anandamide analog, from vehicle to avoid this issue. O-1812 and Delta(9)-THC substituted for each other; however, both drugs were more potent in the O-1812-trained rats. Further, O-1812 only substituted for Delta(9)-THC at response rate decreasing doses. The CB(1) antagonist, SR141716A, blocked the discriminative stimulus effects of both drugs but augmented their rate effects. O-1839, a VR(1) agonist, failed to substitute for either cannabinoid. These results suggest that the discriminative stimulus effects of Delta(9)-THC and O-1812 are similar, but subtle differences also exist.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301634     DOI: 10.1037/1064-1297.12.3.173

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  22 in total

Review 1.  "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.

Authors:  Torbjörn U C Järbe; Roger S Gifford
Journal:  Life Sci       Date:  2013-07-25       Impact factor: 5.037

2.  Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents.

Authors:  Jenny L Wiley; D Matthew Walentiny; M Jerry Wright; Patrick M Beardsley; James J Burston; Justin L Poklis; Aron H Lichtman; Robert E Vann
Journal:  Eur J Pharmacol       Date:  2014-05-22       Impact factor: 4.432

3.  Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.

Authors:  Torbjörn U C Järbe; Quian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

5.  Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.

Authors:  Jenny L Wiley; D Matthew Walentiny; Robert E Vann; Cassandra Y Baskfield
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

6.  Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride.

Authors:  R E Vann; D M Walentiny; J J Burston; K M Tobey; T F Gamage; J L Wiley
Journal:  Neuropharmacology       Date:  2011-10-31       Impact factor: 5.250

7.  Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol.

Authors:  Torbjörn U C Järbe; Chen Li; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2009-11-10       Impact factor: 4.530

Review 8.  Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Addict Biol       Date:  2008-02-14       Impact factor: 4.280

Review 9.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

10.  Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.

Authors:  Torbjörn U C Järbe; Chen Li; Qian Liu; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2008-06-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.